Aug 7 (Reuters) – Sino Biopharmaceutical Limited: * NMPA APPROVES BENMELSTOBART WITH CHEMOTHERAPY FOLLOWED BY ANLOTINIB FOR FIRST-LINE SQ-NSCLC Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Rugby league-Ponga returns to help New Zealand beat Tonga and reach World Cup final
* Ponga returns three weeks after breaking his arm to help New Zealand reach final…
Binance $6.3 billion heist to prompt closer scrutiny by insurers
(Corrects typographical error to "insureds" from "insurers" in paragraph 14) By Noor Zainab Hussain and…
Wall Street stocks in relief rally after heavy AI-related selloff
By Chibuike Oguh and Marc Jones NEW YORK/LONDON, Nov 6 (Reuters) - Wall Street equities…
